A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer

Table 3 Change in target lesion sum of longest diameters from post-chemotherapy baseline to post-chemotherapy nadir

Length of SLD Reduction (mm)	BTH1677/ Bevacizumab/Carboplatin/ Paclitaxel^a (N = 30)	Bevacizumab/Carboplatin/ Paclitaxel^a (N = 13)
> 20	2 (7%)	0
> 10	6 (20%)	0
> 5	10 (33%)	2 (15%)

Abbreviations: N overall sample size, SLD sum of longest diameters
^aNumber of patients continuing in study on maintenance therapy with at least 2 post-chemotherapy tumor assessments based on blinded central radiology review of the primary efficacy population